Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury.

This innovative product, currently undergoing clinical trial application in Europe, holds the promise of potentially making an impact on the lives of countless individuals and their families. Acute spinal cord injuries are life-changing events, and TZ-161 could be a ray of hope for those in need.

The dedication and hard work of the Technophage team, in collaboration with the CRO team from VectorB2B – Drug Development alongside medical professionals and researchers, are paving the way for this remarkable development.

Let’s keep our fingers crossed and support this endeavor by spreading the word about TZ-161 and the positive impact it can have on patients’ lives.